K. Maresh

发表

Prevalence and Prognostic Significance of Preprocedural Cardiac Troponin Elevation Among Patients With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: Results From the Evaluation of Drug Eluting Stents and Ischemic Events Registry

M. Pencina, S. Goldberg, A. Jeremias, 2008, Circulation.

Ticlopidine Enhances the Platelet Inhibitory Capacity of Abciximab In Vitro

R. Jordan, M. Mascelli, N. Kleiman, 2004, Journal of Thrombosis and Thrombolysis.

Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study.

J. Hochman, J. Tcheng, N. Kleiman, 2002, Journal of the American College of Cardiology.

Platelet reactivity in patients with subacute stent thrombosis compared with non-stent-related acute myocardial infarction.

J. Granada, N. Kleiman, E. Lev, 2007, American heart journal.

Dalteparin in combination with abciximab during percutaneous coronary intervention.

N. Kleiman, D. Kereiakes, E. Fry, 2001, American heart journal.

Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions.

R. Jordan, M. Effron, M. Mascelli, 2000, American heart journal.

Platelet reactivity among Asian Indians and Caucasians

M. Vaduganathan, N. Kleiman, E. Lev, 2007, Platelets.

Interventional Cardiology spirin and Clopidogrel Drug Response in atients Undergoing Percutaneous Coronary Intervention he Role of Dual Drug Resistance

N. Kleiman, P. Bray, S. Guthikonda, 2016 .

Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET).

E. Topol, A. Lincoff, N. Kleiman, 2002, American heart journal.

Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide.

S. Solomon, N. Kleiman, U. Arora, 2002, American heart journal.

CLINICAL RESEARCH Interventional Cardiology Aspirin and Clopidogrel Drug Response in Patients Undergoing Percutaneous Coronary Intervention The Role of Dual Drug Resistance

J. Granada, N. Kleiman, E. Lev, 2006 .

Design of a registry to characterize "real-world" outcomes of percutaneous coronary revascularization in the drug-eluting stent era.

David J Cohen, J. Massaro, N. Kleiman, 2005, American heart journal.

Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents.

J. Granada, M. Parikh, N. Kleiman, 2007, JAMA.

Clinical Research Nursing: Development of a residency program

D. Cline, K. Maresh, Kelly La Frentz, 2017, Clinical journal of oncology nursing.

CLINICAL RESEARCH Interventional Cardiology Aspirin and Clopidogrel Drug Response in Patients Undergoing Percutaneous Coronary Intervention The Role of Dual Drug Resistance

J. Granada, N. Kleiman, E. Lev, 2006 .

Effects of abciximab, ticlopidine, and combined Abciximab/Ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty.

L. McIntire, M. Effron, M. Mascelli, 2000, Circulation.